Onco-Innovations Announces Private Placement

Executive Summary

• Onco‑Innovations Limited announces a non‑brokered private placement of up to 1,428,572 units at $1.40 per unit, targeting gross proceeds of up to $2 million.
• Each unit consists of one common share and half of a warrant (full warrant gives the holder the right to purchase one share at $2.00 for 36 months).
• The company also appoints Mr. Christopher Gulka as a new member of the Board of Directors, succeeding Mr. Graydon Bensler.

Key Details

• Units Offered: Up to 1,428,572 units @ $1.40 per unit → gross proceeds up to $2,000,000.
• Unit Composition: 1 common share + ½ of a common‑share purchase warrant (full warrant = right to buy one share at $2.00 for 36 months).
• Admin Fee Shares: Additional shares equal to 1.0 % of the total shares issued in the placement will be issued as an administrative fee to a third‑party facilitator.
• Finders’ Fees/Warrants: Company may issue finders’ fees and/or finders’ warrants on the same terms as the primary warrants to parties that introduce subscribers.
• Closing Conditions: Subject to regulatory approvals, hold period of four months + one day, and other customary conditions.
• Use of Proceeds: General corporate and working‑capital purposes, including advancement of operational and R&D objectives and investor‑relations activities.
• Board Appointment: Christopher Gulka, CFA, CPA, appointed to the Board effective immediately; brings 30+ years in capital markets and corporate finance. Replaces Graydon Bensler.

Notable Quotes

• “The proceeds from this private placement will support our ongoing research initiatives and strengthen our financial position as we continue to advance innovative oncology solutions.” – Thomas O’Shaughnessy, CEO

Materiality Assessment: Material – Positive (significant capital raise and board change expected to positively impact the company’s operations and strategic execution).